You are here

Stevanato Group adds Microsoft mixed reality solutions to pharma packaging operations

Stevanato Group, a manufacturer of glass and plastic packaging for the pharmaceutical industry based in Italy and with 14 production plants in 9 countries, announced they have broadened their Microsoft cloud investment with new mixed reality tech for their manufacturing and quality programs.

Stevanato Group strengthens its collaboration with Microsoft Italy in support of its growth program through the use of new technologies to meet the challenges the pharmaceutical industry is currently experiencing as a result of the pandemic. The Group, which has over 4,200 employees and 14 production facilities in 9 countries, is playing a key role in the production of plastic components for diagnostic tests and glass primary packaging for drugs. It provides packaging and syringes for the major international anti-COVID-19 vaccine programs being developed, as well as pharmaceutical inspection equipmentCloud Computing is, thus, strategic for business continuity during this delicate phase in which Stevanato Group has never ceased production, with the goal of providing support to the pharmaceutical industry.

Stevanato Group’s constant growth is sustained by an extensive digital transformation plan which also includes the development of a series of applications which, leveraging Microsoft Mixed Reality technologies, are designed to respond to the current needs of the pharmaceutical sector. For example, a Virtual Audit plan was launched, thanks to which the Stevanato Group quality teams wear the Microsoft HoloLens2 holographic headset with integrated Dynamics Remote Assist. This allows them to move throughout the installation to show customers in remote connection all processes, including production phases and lab testing. This also makes it possible to perform a remote quality system audit to ascertain that the installation complies with required standards and customer needs without requiring an interruption in the pharmaceutical supply chain, which is even more strategic during the pandemic. In addition, the HoloLens headset also makes it possible to perform the Virtual FAT (Factory Acceptance Test) — the final pre-delivery inspection that assures the remotely connected customer that the equipment is functioning properly. While wearing the headset, a technician can demonstrate machine components, start it up and share documentation. Remote acceptance of equipment for the inspection of drugs and vaccines being developed makes it possible to accelerate delivery to pharmaceutical companies, a factor that is critical in this period when the company has to manage large volumes on a short time frame. 

The new frontier of Stevanato Group digital transformation process also includes the development of Artificial Intelligence to improve the performance of inspection systems and detection of defective glass containers filled with a range of drugs. In fact, a project designed to make inspection equipment supplied by the Group even more intelligent was launched in recent months, and it will be completed by 2021. Artificial Intelligence will be an additional ally of Stevanato Group in guaranteeing maximum quality to the pharmaceutical industry, by reducing potential errors and quickly detecting defective products along the production line. The integrity of these containers is essential and, thanks to Microsoft AI integrated into Stevanato Group inspection equipment, pharmaceutical companies will be able to make use of reliable algorithms to identify any defects even more easily and guarantee the highest standards of drug and vaccine conformity. False positives can be reduced by 10-fold, also decreasing container production waste, and detection rate can be improved by 5%.

These projects are part of the broader Digital Transformation plan of Stevanato Group, which is aimed to the completion of the New Digital Ecosystem by 2022. Within this context, the Group has worked side-by-side with Microsoft, focusing on a 360° Cloud approach. Over the last two years, Microsoft 365 cloud platform for productivity and security was adopted, utilizing Teams for collaboration, the New Digital Architecture on Microsoft Azure cloud was extended with advantages in terms of scalability and computing capacity, and Microsoft Dynamics 365 cloud platform was implemented to provide a unified picture of customers and sales processes across all business lines. An integral part of the new digital ecosystem will also be the Data Strategy focused on Azure Synapse platform, the analysis service that combines data warehousing features with Big Data analysis, making it possible to carry out queries on a large scale, while providing analysis with unparalleled rapidity — up to 14 times faster — and detailed information for Business Intelligence and Machine Learning. All this with the guarantee of maximum security and privacy, which is a strategic factor when working with the pharmaceutical companies involved in drug patents and research projects, such as those for the new anti-COVID-19 vaccine.